Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real-world study

被引:2
作者
Zhang, Xudong [1 ]
Qiao, Honghan [1 ]
Chai, Xiaofei [1 ]
Gao, Xue [2 ]
Ma, Rongjun [3 ]
Li, Yufu [2 ]
Zhu, Zunmin [3 ]
Zhang, Mingzhi [1 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[2] Henan Canc Hosp, Zhengzhou, Peoples R China
[3] Henan Prov Peoples Hosp, Zhengzhou, Peoples R China
关键词
brentuximab vedotin; effectiveness; lymphoma; real-world study; safety; CELL LYMPHOMA; CD30; EXPRESSION;
D O I
10.1002/cam4.6733
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Brentuximab vedotin (BV) was approved as a therapy for patients with CD30-positive lymphoma in China in 2020 based on the results of multiple clinical trails. Few Chinese real-world data of its use are yet available. Herein, we present the application situation of BV in patients with lymphoma among different hospitals in Henan province in China under real-world conditions.Methods: This was a multicenter and retrospective study in 104 patients with lymphoma who received BV for the first time between August 2020 and September 2022 across eight centers in Henan province. Data on the clinical use, effectiveness and adverse events (AEs) of BV were extracted from patient medical records. Short-term effectiveness was assessed based on objective response rate (ORR), complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). Progression-free survival (PFS) and overall survival (OS) were calculated using Kaplan-Meier method. Safety was also evaluated in our study.Results: 104 lymphoma patients were enrolled in our study, who had completed a median of two cycles (range,1-8) of BV-based treatment. A total of 72.1% of patients were relapsed/refractory (R/R) lymphoma, and only 27.9% were previously untreated lymphoma who received BV in frontline treatment settings. Among them who received effectiveness evaluation, the ORR achieved 64.5% (CR 25.8%, PR 38.7%). After a median follow-up of 11 months, the 6-month PFS rate and OS rate achieved 77.2% and 90.1% respectively, and the 12-month PFS rate and OS rate achieved 77.2% and 79.9% respectively. In general, BV-based treatment was well-tolerated, with 38.5% incidence of grade >= 3 AEs. The most commonly reported AEs were hematologic disorders, especially neutropenia, with the incidence reaching 50.0%.Conclusions: BV-based regimens could be a promising therapeutic option with remarkable effectiveness and moderate toxicity in treating Chinese lymphoma patients with CD30 expression.
引用
收藏
页码:21725 / 21734
页数:10
相关论文
共 27 条
[1]   Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma [J].
Ansell, Stephen M. ;
Radford, John ;
Connors, Joseph M. ;
Dlugosz-Danecka, Monika ;
Kim, Won-Seog ;
Gallamini, Andrea ;
Ramchandren, Radhakrishnan ;
Friedberg, Jonathan W. ;
Advani, Ranjana ;
Hutchings, Martin ;
Evens, Andrew M. ;
Smolewski, Piotr ;
Savage, Kerry J. ;
Bartlett, Nancy L. ;
Eom, Hyeon-Seok ;
Abramson, Jeremy S. ;
Dong, Cassie ;
Campana, Frank ;
Fenton, Keenan ;
Puhlmann, Markus ;
Straus, David J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (04) :310-320
[2]   Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT [J].
Badar, Talha ;
Epperla, Narendranath ;
Szabo, Aniko ;
Borson, Steven ;
Vaughn, John ;
George, Gemlyn ;
Saini, Neeraj ;
Shah, Abdul Rashid ;
Patel, Romil D. ;
Ahmed, Sairah ;
Shah, Nirav N. ;
Cashen, Amanda F. ;
Hamadani, Mehdi ;
Fenske, Timothy S. .
BLOOD ADVANCES, 2020, 4 (01) :47-54
[3]   Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies [J].
Bartlett, Nancy L. ;
Chen, Robert ;
Fanale, Michelle A. ;
Brice, Pauline ;
Gopal, Ajay ;
Smith, Scott E. ;
Advani, Ranjana ;
Matous, Jeffrey V. ;
Ramchandren, Radhakrishnan ;
Rosenblatt, Joseph D. ;
Huebner, Dirk ;
Levine, Pamela ;
Grove, Laurie ;
Forero-Torres, Andres .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
[4]   Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma [J].
Chen, Robert ;
Gopal, Ajay K. ;
Smith, Scott E. ;
Ansell, Stephen M. ;
Rosenblatt, Joseph D. ;
Savage, Kerry J. ;
Connors, Joseph M. ;
Engert, Andreas ;
Larsen, Emily K. ;
Huebner, Dirk ;
Fong, Abraham ;
Younes, Anas .
BLOOD, 2016, 128 (12) :1562-1566
[5]  
Dürkop H, 2000, J PATHOL, V190, P613
[6]   Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study [J].
Fukuhara, Noriko ;
Yamamoto, Go ;
Tsujimura, Hideki ;
Chou, Takaaki ;
Shibayama, Hirohiko ;
Yanai, Tomoko ;
Shibuya, Kazunori ;
Izutsu, Koji .
LEUKEMIA & LYMPHOMA, 2020, 61 (01) :176-180
[7]   Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis [J].
Gao, Siyuan ;
Zhang, Mei ;
Wu, Kaishan ;
Zhu, Jianhong ;
He, Zhichao ;
Li, Jianfang ;
Chen, Chuxiong ;
Qiu, Kaifeng ;
Yu, Xiaoxia ;
Wu, Junyan .
EXPERT OPINION ON DRUG SAFETY, 2020, 19 (05) :617-623
[8]   The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma [J].
Horwitz, S. ;
O'Connor, O. A. ;
Pro, B. ;
Trumper, L. ;
Iyer, S. ;
Advani, R. ;
Bartlett, N. L. ;
Christensen, J. H. ;
Morschhauser, F. ;
Domingo-Domenech, E. ;
Rossi, G. ;
Kim, W. S. ;
Feldman, T. ;
Menne, T. ;
Belada, D. ;
Illes, A. ;
Tobinai, K. ;
Tsukasaki, K. ;
Yeh, S-P ;
Shustov, A. ;
Huettmann, A. ;
Savage, K. J. ;
Yuen, S. ;
Zinzani, P. L. ;
Miao, H. ;
Bunn, V ;
Fenton, K. ;
Fanale, M. ;
Puhlmann, M. ;
Illidge, T. .
ANNALS OF ONCOLOGY, 2022, 33 (03) :288-298
[9]   Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression [J].
Jacobsen, Eric D. ;
Sharman, Jeff P. ;
Oki, Yasuhiro ;
Advani, Ranjana H. ;
Winter, Jane N. ;
Bello, Celeste M. ;
Spitzer, Gary ;
Palanca-Wessels, Maria Corinna ;
Kennedy, Dana A. ;
Levine, Pamela ;
Yang, Jing ;
Bartlett, Nancy L. .
BLOOD, 2015, 125 (09) :1394-1402
[10]   Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma [J].
Jagadeesh, Deepa ;
Horwitz, Steve ;
Bartlett, Nancy L. ;
Kim, Youn ;
Jacobsen, Eric ;
Duvic, Madeleine ;
Little, Meredith ;
Trepicchio, William ;
Fenton, Keenan ;
Onsum, Matthew ;
Lisano, Julie ;
Advani, Ranjana .
ONCOLOGIST, 2022, 27 (10) :864-873